|1.||Rosendaal, F R: 26 articles (01/2013 - 03/2000)|
|2.||Rosendaal, Frits R: 21 articles (08/2012 - 01/2002)|
|3.||Akar, Nejat: 19 articles (08/2013 - 05/2002)|
|4.||Glueck, Charles J: 17 articles (12/2015 - 06/2002)|
|5.||Wang, Ping: 15 articles (12/2015 - 06/2002)|
|6.||Simioni, Paolo: 14 articles (12/2015 - 03/2002)|
|7.||De Stefano, Valerio: 14 articles (10/2013 - 05/2002)|
|8.||Almawi, Wassim Y: 14 articles (08/2013 - 10/2002)|
|9.||Martinelli, Ida: 13 articles (12/2015 - 05/2002)|
|10.||Tormene, D: 13 articles (09/2014 - 01/2000)|
|1.||Activated Protein C Resistance (APC Resistance)
02/01/1997 - "Thus the activated protein C resistance assay is not cost-effective in ruling out factor V Leiden in this population."
09/01/2013 - "An improved algorithm for activated protein C resistance and factor V Leiden screening."
05/01/2015 - "Our study emphasizes the presence of other contributory factors towards APC resistance rather than FV Leiden alone. "
01/01/2007 - "In both studies the Pefakit assay showed 100% sensitivity and 100% specificity for detection of the factor V Leiden mutation, compared to 93.1% sensitivity and 93.0% specificity for the COATEST APC Resistance V in the IMCLD study and 93.9% sensitivity and 95.6% specificity in the DUMC study. "
09/01/2005 - "Coagulation studies performed in the neonatal period and at the age of 18 months revealed activated protein C resistance due to factor V Leiden mutation (R506Q). "
04/01/1997 - "Risks for venous thromboembolism in heterozygous carriers of factor V Leiden mutation increased with age at a rate significantly greater than that in noncarriers. "
01/01/2013 - "The objective of this study was to compare standard vs. lifelong anticoagulation in 20-year-old factor V Leiden heterozygotes with unprovoked venous thromboembolism. "
01/01/2012 - "The role of Factor V Leiden in adult patients with venous thromboembolism: a meta-analysis of published studies from Turkey."
11/01/2010 - "The objective of the study was to determine the prevalence of the factor V Leiden (FVL) mutation and its association with obstetric complications, blood loss during delivery, and venous thromboembolism (VTE). "
02/01/2007 - "Update on factor V Leiden association with venous thromboembolism in the LITE Study."
01/01/2008 - "This report suggests that postoperative anticoagulation may be helpful for the successful maturation of vascular anastomoses in children with underlying acquired or hereditary risk factors for thrombosis including factor V Leiden mutation."
09/01/2010 - "This study was carried out to evaluate if increased numbers or procoagulant potential of circulating MP contribute to the heterogeneity in occurrence of thrombosis in heterozygotes carrying Factor V Leiden (FVL) mutation. "
01/01/2010 - "Thrombosis risk panel studies showed factor V Leiden homozygote mutation. "
04/01/2009 - "Several recent studies report a further increased risk of thrombosis by an association between the AB alleles of the ABO blood group and Factor V Leiden. "
06/01/2008 - "The results of this study also indicate that to ensure early diagnosis, routine screening for thrombosis should be performed in patients with a cardiac defect and that screening for factor V Leiden and PT 20210G-A mutations and other genetic risk factors should be included when assessing all patients with cardiac defects who present with a thrombosis, whether or not a predisposing factor has been identified."
03/01/2002 - "However, the marginal cost-effectiveness ratio was highly dependent on the rate of recurrent VTE, the risk of major hemorrhage, prevalence of factor V Leiden, patient age, and the efficacy of anticoagulation therapy. "
01/01/2013 - "Studies assessing bleeding risk with anticoagulation in factor V Leiden heterozygotes and the costs of indefinite anticoagulation are needed to determine if lifelong anticoagulation is the optimal strategy."
01/01/1998 - "Trial endpoints will include recurrent VTE, major bleeding episodes and all-cause mortality in the total patient population and separately in those patients with factor V Leiden. "
03/16/2014 - "This is the first report in the medical literature of factor V Leiden mutation in an EDS patient which made the management of our patient challenging with propensity to both bleeding and clotting. "
05/01/2013 - "Factor V Leiden testing in a hypothetical cohort of 10,000 women led to 7 fewer venous thromboembolic events, 90 fewer pregnancy losses, and an increase of 17 major bleeding events. "
01/01/2005 - "Who, what, and when to test continue to be controversial and challenging questions (2); however, laboratories developing new or improved mutation detection methodologies have used the most commonly screened inherited thrombophilia polymorphism, factor V Leiden (R506Q), for many years (3). "
03/16/2009 - "A heterozygotic mutation for factor V Leiden was found in a hypercoagulability study that was later performed. "
10/01/1996 - "The diagnostic strategies and clinical characteristics of thrombophilia associated with heterozygous or homozygous factor V Leiden mutation have been determined according to the literature and to a personal study in 51 families. "
10/03/2015 - "The thrombophilia workup revealed either the presence of congenital homozygous PC deficiency, prothrombotic polymorphisms (factor V Leiden and FIIG20210A heterozygosity), acquired PC/PS deficiency, or no discernible thrombophilia. "
09/01/2014 - "With the exception of factor V Leiden mutation, other types of congenital thrombophilia are almost negligible among older women. "
|1.||Prothrombin (Factor II)
|2.||Factor V (Coagulation Factor V)
|3.||DNA (Deoxyribonucleic Acid)
|4.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|4.||Drug Therapy (Chemotherapy)